For the Inventor, By the Inventor

Enter inventor name

Tsu-An Hsu

USPTO Granted Patents = 17 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 56(Granted Patents)

Location History:

Taipei, TW (2004 - 2016)
Miaoli County, TW (2013 - 2023)

Company Filing History:

National Health Research Institutes

Chung Yuan Christian University

Anbogen Therapeutics, Inc

International Chlorella Co., Ltd.

5. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

Loading Chart...

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12252469 - Crystalline forms of (E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide (2025-03-18),

2. 12240858 - Crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2- enamide free base (2025-03-04),

3. 11623951 - Antibodies to R-spondin 3 (2023-04-11),

4. 11084873 - Anti-Abeta antibodies and uses thereof (2021-08-10),

5. 9255072 - Pyrazole compounds and thiazole compounds as protein kinases inhibitors (2016-02-09),

6. 8710079 - Quinoline compounds and their use for treating viral infection (2014-04-29),

7. 8507502 - Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors (2013-08-13),

8. 8138194 - Fused bicyclic pyrimidine compounds as aurora kinase inhibitors (2012-03-20),

9. 8048426 - [object Object] (2011-11-01),

10. 7985763 - Hepatitis C virus inhibitors (2011-07-26),

11. 7939523 - Imidazolidinone and imidazolidinethione derivatives (2011-05-10),

12. 7897764 - Thiourea derivatives (2011-03-01),

13. 7588885 - Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation (2009-09-15),

14. 7544712 - Treatment of coronavirus infection (2009-06-09),

15. 7449478 - Indole compounds (2008-11-11),

Title: Innovator Spotlight - Tsu-An Hsu: Pioneering Antibody Research in Taipei

Introduction: Tsu-An Hsu, a distinguished inventor based in Taipei, TW, is recognized for his groundbreaking contributions in the field of antibody research. With an impressive portfolio of 15 patents, Hsu's work focuses on developing antibodies for the treatment of cancer and other diseases.

Latest Patents: Among his recent patents, Tsu-An Hsu has made significant advancements in the development of antibodies targeting specific proteins. One notable patent is on Antibodies to R-spondin 3, which describes isolated antibodies that bind specifically to RSPO3 for cancer treatment. Another key patent is on Anti-Abeta antibodies, showcasing antibodies designed to specifically bind to Aβ or its modified forms, offering potential therapeutic applications.

Career Highlights: Tsu-An Hsu has held pivotal roles at esteemed institutions such as the National Health Research Institutes and Chung Yuan Christian University. His expertise and dedication have led to the successful filing of multiple patents, securing his position as a leading figure in the field of antibody research.

Collaborations: Throughout his career, Tsu-An Hsu has collaborated with notable researchers, including Yu-Sheng Chao and Hsing-Pang Hsieh. These collaborations have facilitated the exchange of innovative ideas and contributed to the development of novel antibody-based therapies.

Conclusion: In conclusion, Tsu-An Hsu's relentless pursuit of innovation in antibody research has significantly impacted the medical field. His pioneering work in developing targeted antibodies for cancer treatment and disease detection underscores his commitment to advancing healthcare solutions. Tsu-An Hsu stands as a testament to the potential of innovative research in shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…